The latest news on MS treatments, research and specialist services.
MS Trust news
News from the MS Trust
Views and comment
MS Trust staff, MS health professionals and people with MS offer their perspectives on hot topics in the world of MS
Our free, quarterly newsletter for people with multiple sclerosis, their family and friends and supporters of the MS Trust.
Read our latest news
As he starts his training, David Martin tells us why he will be cycling from London to Amsterdam with a team of over 40 other MS Trust supporters.
- The effect of MS on work - a teacher's story
- MS and cancer
- Chickenpox, shingles and MS
- Mild cognitive impairment and exercise
- Stem cell therapy
- NICE recommends restricting choice of MS drugs
- MS treatment optimism
- Having MS and other conditions
- Diagnostic criteria updated
When Jerry Burnie joined a wheelchair basketball team four years ago, he could never have imagined just how much of a positive difference it would make to his life.
Katie Ellis tells us about how she was inspired to found the Able Label, specialising in adaptive clothing for women.
Medday, the company developing high dose biotin for progressive MS, has told the European Medicines Agency that it wishes to withdraw its licence application.
- Gilenya and Betaferon compared
- Pain prevalence and treatment
- Cold water in the mouth helps heat sensitivity
- Benefit reassessment concerns
- Review of the year - MS in America
Larissa Thomas was diagnosed with MS in July last year. Here she talks tattoos, smiling through the pain and why she’s determined to make the best of things.
- Diet may improve MS
- Laquinimod trial for PPMS unsuccessful
- Epilepsy and MS
- Stem cell therapy consensus report
Paralympic champion Kadeena Cox, who was diagnosed with MS in 2014, talks sport, MS and the people who inspire her.
- Shortage of neurology services
- Diet affects gut bacteria and modulates immune system
- Cognitive symptoms in early-stage MS
- High number of people with MS turned down for PIP
- Biotin may affect medical tests
The outstanding work of MS specialist nurses, neurologists, allied health professionals and multi-disciplinary teams from across the UK was celebrated at the third annual QuDoS in MS recognition programme.
- Mark Lewis and stem cells
- Self-management may help mood
- CCSVI trial disappointing
- Why smoking is bad for people with MS
- Ocrevus licensed for relapsing and progressive MS
- Gilenya effective for children with MS
- Social care failing people with disabilities
- Wii a useful way to exercise
School friends Emma and Marc took on the Descente London Duathlon this September, raising £700 in sponsorship.
The European Medicines Agency recommends licensing for ocrelizumab (Ocrevus) for treating active relapsing and early primary progressive MS.
Reports of studies presented at the ECTRIMS meeting that took place from 25-28 October 2017. Topics include research into existing and new drugs for relapsing and progressive MS and lifestyle factors in MS.